Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 11
Submit an article Journal homepage
1,373
Views
19
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells

Megan Jo MillerDepartment of Microbiology; The Ohio State University, Columbus, OHUSA
,
Kevin C FoyDepartment of Obstetrics and Gynecology; The Ohio State University Wexner Medical Center; Columbus, OHUSA
,
Jay P OverholserDepartment of Obstetrics and Gynecology; The Ohio State University Wexner Medical Center; Columbus, OHUSA
,
Rita NahtaDepartment of Pharmacology; Emory University, Atlanta, GAUSA
&
Pravin TP KaumayaDepartment of Microbiology; The Ohio State University, Columbus, OHUSA;Department of Obstetrics and Gynecology; The Ohio State University Wexner Medical Center; Columbus, OHUSA;The James Cancer Hospital and Solove Research Institute; and the Comprehensive Cancer Center; The Ohio State University, Columbus, OHUSACorrespondence[email protected]
Article: e956012 | Received 08 Jul 2014, Accepted 14 Aug 2014, Published online: 17 Dec 2014

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Pravin T. P. Kaumaya, Linlin Guo, Jay Overholser, Manuel L. Penichet & Tanios Bekaii-Saab. (2020) Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. OncoImmunology 9:1.
Read now
Pravin TP Kaumaya. (2015) A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Human Vaccines & Immunotherapeutics 11:6, pages 1368-1386.
Read now

Articles from other publishers (17)

Fatemeh Zahedipour, Khadijeh Jamialahmadi, Parvin Zamani & Mahmoud Reza Jaafari. (2023) Improving the efficacy of peptide vaccines in cancer immunotherapy. International Immunopharmacology 123, pages 110721.
Crossref
Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2022) HER3 in cancer: from the bench to the bedside. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Yasar Ahmed, Thamir Mahgoub, Maha Al Sindi & José J. Berenguer‐Pina. (2022) New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer. MedComm – Oncology 1:2.
Crossref
Peng Ye, Yiran Wang, Ruiqi Li, Wanlu Chen, Lu Wan & Peiling Cai. (2022) The HER family as therapeutic targets in colorectal cancer. Critical Reviews in Oncology/Hematology 174, pages 103681.
Crossref
Linlin Guo & Pravin T. P. Kaumaya. (2021) First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. British Journal of Cancer 125:2, pages 152-154.
Crossref
Gonzalo Recondo & Laura Mezquita. (2020) Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncology 16:23, pages 1659-1664.
Crossref
Pravin TP Kaumaya. (2020) B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology.
Crossref
Laurel E. Black, Jody F. Longo & Steven L. Carroll. (2019) Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. The American Journal of Pathology 189:10, pages 1898-1912.
Crossref
Tanios Bekaii-Saab, Robert Wesolowski, Daniel H. Ahn, Christina Wu, Amir Mortazavi, Maryam Lustberg, Bhuvaneswari Ramaswamy, Jeffrey Fowler, Lai Wei, Jay Overholser & Pravin T.P. Kaumaya. (2019) Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clinical Cancer Research 25:12, pages 3495-3507.
Crossref
Ye Won Chung, Seongmin Kim, Jin Hwa Hong, Jae Kwan Lee, Nak Woo Lee, Young Seok Lee & Jae Yun Song. (2019) Overexpression of HER2/HER3 and clinical feature of ovarian cancer. Journal of Gynecologic Oncology 30:5.
Crossref
Rosalin Mishra, Hima Patel, Samar Alanazi, Long Yuan & Joan T. Garrett. (2018) HER3 signaling and targeted therapy in cancer. Oncology Reviews.
Crossref
Dane A. Hayes, Dale A. Kunde, Robyn L. Taylor, Stephen B. Pyecroft, Sukhwinder Singh Sohal & Elizabeth T. Snow. (2017) ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLOS ONE 12:6, pages e0177919.
Crossref
Dong Jin, Xin Yu, Bing Chen, Zhitao Li, Jia Ding, Xiuyun Zhao & Gaofu Qi. (2017) Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model. Immunotherapy 9:7, pages 537-553.
Crossref
Samuel C. Wagner, Thomas E. Ichim, Vladimir Bogin, Wei-Ping Min, Francisco Silva, Amit N. Patel & Santosh Kesari. (2017) Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget 8:17, pages 28595-28613.
Crossref
P.T.P. Kaumaya & T. Bekaii-Saab. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 1 31 .
Guido Kroemer, Laura Senovilla, Lorenzo Galluzzi, Fabrice André & Laurence Zitvogel. (2015) Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine 21:10, pages 1128-1138.
Crossref
Jay Overholser, Kristen Ambegaokar, Siobhan Eze, Eduardo Sanabria-Figueroa, Rita Nahta, Tanios Bekaii-Saab & Pravin Kaumaya. (2015) Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines 3:3, pages 519-543.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.